Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
about
Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1Effect of alosetron on theophylline pharmacokineticsInduction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formulaA re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.Enhanced theophylline metabolism in patients with bronchial asthma at age 4 and under.Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans.Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.Clinically significant pharmacokinetic interactions between dietary caffeine and medications.Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary diseasePharmacogenetics: the therapeutic drug monitoring of the future?Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker.St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers.Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Hormonal regulation of CYP1A expression.Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolismProfound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies.Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.Acute and chronic human toxicity of theophylline.Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites.Regulation of cytochromes P450 during inflammation and infection.Involvement of CYP1A2 in mexiletine metabolism.Down-regulation of the hepatic cytochrome P450 by an acute inflammatory reaction: implication of mediators in human and animal serum and in the liver.Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation.Pharmacokinetic analysis of theophylline to assess noncompliance in therapy.The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6.The effect of orally administered marbofloxacin on the pharmacokinetics of theophylline.Alteration of the pharmacokinetics of theophylline by rutaecarpine, an alkaloid of the medicinal herb Evodia rutaecarpa, in rats.Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline.Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.
P2860
Q26799149-9BB02F03-D093-4F59-84ED-F051365A7B1BQ28365915-408BB5C7-953E-4938-A2B2-6CEDC4C17FDFQ28391251-A3CCEAC3-932D-4475-B42F-4856CBCAADEAQ30786488-80458C6D-6008-4F96-B03C-83E3BFE5BD5BQ30800376-16C6D907-2334-4DBC-9E86-DD7D7DD4D368Q33566153-989EFA0B-674E-4AA9-805B-E35BB01C79E3Q33696922-9CF373BB-E572-42E2-B3B1-1AF927F1AD77Q33858325-9DD4315E-D22F-4A69-A677-14B492A2837AQ33916981-AA7AD612-DFCC-4115-974C-F3BCB88BF3C2Q34347707-9AE091F1-1D3C-4389-84AD-571EEAFF4D88Q34458332-AB5F2B74-E941-4D3E-998D-817EC91472BEQ34743662-15059B4B-A241-4CBE-B157-8E26CF3BF5AFQ34976869-C1332195-46AD-4521-A3F4-F61AA64A3EE2Q35015993-D774585A-30C9-4E70-92D1-BF204AC953A0Q35126115-A6E9A24F-5ECE-4591-8E23-BF8838A3C549Q35210306-4B219744-27E3-49F6-9B6D-8C44F14F8658Q35624622-5F45B84C-E315-4F36-8714-804D7662F9D2Q35803009-F457C986-C6A5-431A-9BEF-8FFBF740D82AQ35827012-9D4E75BF-BF5A-4829-873D-51FD44FDFDD7Q37079954-2709FCFB-20F3-4076-AFC2-C7C8CFBE42BAQ37559609-441FACF7-143E-4825-B5C8-F426DF84CBB4Q37720189-F4276D97-B4F3-48F3-8FEB-10ACDD678ED6Q37872786-97DC5A40-8FFF-4D92-88BE-2263BBB28AE0Q38103885-631B8A16-CD14-43A1-8375-E265781E96D8Q38176575-59AB4298-AB77-41ED-BDA3-1FABE4FE71ECQ39558046-926F6DA6-F1FF-436E-A6FB-9CF8FE5329D6Q39782469-B55DF2C5-C422-4E3E-96E5-EC217A334165Q41102634-7734FF1D-FF90-4962-A5D7-940AF1A7FA50Q41247453-9DC16BE8-1FAD-4640-9670-1F3EC43D3F79Q41469292-13D3E7DA-5CB0-430B-96BF-55D6D149C40AQ41676809-CF4E93C6-7197-4EBF-AC22-E7BF8AFB643AQ42176480-DCB0040A-B00E-4441-8B78-1DBAC5C67416Q42272588-A2344F6A-10D7-4C2B-B3DF-81AC9F77F62CQ43938834-39FE8A0A-DC3D-4586-8F02-EF11D2C766C0Q43972199-2D780FE2-13BD-4116-B23F-4ABDDD1D0379Q43997702-FA85EE44-E435-4952-B36E-8E60BD013637Q44624031-814BA5E7-31EC-45D2-B923-B6A02913B5E6Q45273774-4CF69747-7B48-46CE-87D9-F93376BC50ECQ45354207-46229EE9-EE10-484E-80A0-B6F1A2A0BE1BQ46522691-C97A86F5-C180-4886-A75C-4B36CA9372A0
P2860
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@ast
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@en
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@nl
type
label
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@ast
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@en
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@nl
prefLabel
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@ast
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@en
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@nl
P2093
P2860
P1476
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1995.TB04455.X
P407
P577
1995-03-01T00:00:00Z